Bowen Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bowen Li has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Aoshuang Cheng
Sun Yat-Sen Memorial Hospital 1 Guangzhou, Guangdong
18 shared publications - Chunxian Huang
Sun Yat-Sen Memorial Hospital 1 Guangzhou, Guangdong
18 shared publications - Chuying Huo
Sun Yat-Sen Memorial Hospital 1 Guangzhou, Guangdong
18 shared publications - Dongdong Xu
Sun Yat-sen Memorial Hospital, Sun Yat-sen University 4 Guangzhou, Guangdong
18 shared publications - Dongdong Ye
Sun Yat-sen Memorial Hospital 2 Guangzhou
18 shared publications - Huaiwu Lu
Department of Gynecologic Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
18 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Data from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
Elevated neutrophil-to-lymphocyte ratio (NLR) has been associated with platinum resistance and poor outcomes in high-grade serous ovarian cancer (HGSOC), but the biological basis of this association remains unclear. We retrospectively analyzed 434 patients with HGSOC treated with platinum-based chemotherapy and found that elevated NLR was an independent predictor of platinum resistance. To further investigate the cellular basis of this association, we performed immunohistochemistry (IHC), proteomic profiling, and single-cell RNA sequencing on patient samples. These analyses identified a distinct subpopulation of V-domain immunoglobulin suppressor of T-cell activation–positive neutrophils (VISTA+Neus) enriched in resistant tumors. High VISTA+Neus density was linked to shorter progression-free survival and showed greater predictive value for resistance than total neutrophils. Spatial and multicolor IHC analyses further showed that VISTA+Neus were associated with reduced CD8+ T-cell infiltration and cytotoxic features. Functional validation in an immunocompetent mouse model showed that anti-VISTA plus cisplatin reduced tumor growth, decreased neutrophil abundance, and increased CD8+ T-cell infiltration and granzyme B expression. CD8+ T-cell depletion markedly attenuated the therapeutic benefit of the combination. These findings support VISTA+Neus as a potential immunosuppressive neutrophil subset associated with platinum resistance and CD8+ T-cell suppression in HGSO, and support further investigation of VISTA-targeted strategies and the potential biomarker value of VISTA+Neus.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
Elevated neutrophil-to-lymphocyte ratio (NLR) has been associated with platinum resistance and poor outcomes in high-grade serous ovarian cancer (HGSOC), but the biological basis of this association remains unclear. We retrospectively analyzed 434 patients with HGSOC treated with platinum-based chemotherapy and found that elevated NLR was an independent predictor of platinum resistance. To further investigate the cellular basis of this association, we performed immunohistochemistry (IHC), proteomic profiling, and single-cell RNA sequencing on patient samples. These analyses identified a distinct subpopulation of V-domain immunoglobulin suppressor of T-cell activation–positive neutrophils (VISTA+Neus) enriched in resistant tumors. High VISTA+Neus density was linked to shorter progression-free survival and showed greater predictive value for resistance than total neutrophils. Spatial and multicolor IHC analyses further showed that VISTA+Neus were associated with reduced CD8+ T-cell infiltration and cytotoxic features. Functional validation in an immunocompetent mouse model showed that anti-VISTA plus cisplatin reduced tumor growth, decreased neutrophil abundance, and increased CD8+ T-cell infiltration and granzyme B expression. CD8+ T-cell depletion markedly attenuated the therapeutic benefit of the combination. These findings support VISTA+Neus as a potential immunosuppressive neutrophil subset associated with platinum resistance and CD8+ T-cell suppression in HGSO, and support further investigation of VISTA-targeted strategies and the potential biomarker value of VISTA+Neus.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
The forest maps exhibit the results from univariable and multivariable logistic regression.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
The forest maps exhibit the results from univariable and multivariable logistic regression.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
Inverse spatial relationship between VISTA+Neus and GZMB+CD8+T cells in HGSOC patients.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
Inverse spatial relationship between VISTA+Neus and GZMB+CD8+T cells in HGSOC patients.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
Representative gating strategy for neutrophils (Neus) and CD8+T cells in tumor tissues and peripheral blood from the CD8 depletion experiment.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
Representative gating strategy for neutrophils (Neus) and CD8+T cells in tumor tissues and peripheral blood from the CD8 depletion experiment.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
NLR level is associated with outcomes in HGSOC patients treated with platinum-based chemotherapy.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
NLR level is associated with outcomes in HGSOC patients treated with platinum-based chemotherapy.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
CD8+T-cell depletion attenuates the efficacy of cisplatin plus anti-VISTA therapy in ovarian cancer.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
CD8+T-cell depletion attenuates the efficacy of cisplatin plus anti-VISTA therapy in ovarian cancer.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
Kaplan-Meier analyses of PFS and OS according to NLR in the pretreatment stage III-IV HGSOC subgroup of the discovery cohort.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
Kaplan-Meier analyses of PFS and OS according to NLR in the pretreatment stage III-IV HGSOC subgroup of the discovery cohort.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
Activation of neutrophil-related pathways correlates with platinum resistance in HGSOC.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
Activation of neutrophil-related pathways correlates with platinum resistance in HGSOC.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
Association of VISTA, TCIRG1 and LILRB3 with outcomes in HGSOC.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
Association of VISTA, TCIRG1 and LILRB3 with outcomes in HGSOC.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
Dimensionality reduction clustering process and the signature genes of all cell types.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
Dimensionality reduction clustering process and the signature genes of all cell types.